الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 278 |  |  |
| | | from | 278 | | |
Abstract
The potential of nanobiomedical field for developing a promising therapeutic nano-sized drug delivery system is seen to be a great pharmaceutical trend for encapsulation and release of various antineoplastic drugs. Chemotherapy is a major therapeutic approach for the treatment of localized and metastasized cancers. Although Doxorubicin (Dox) possesses abroad spectrum of anticancer activity, its clinical use is limited because of it causes heart and renal failure. These nanoaparticles were used as poly load of anticancer Dox to form safer and non-toxic anticancer drug. MiRNAs are good candidates for biomarkers of various diseases and tissue destructions. Additionally, miRNAs have been also studied as possible biomarkers for toxicological studies, and they’re used as biomarkers of drug- or chemical-induced tissue injury for safety assessment. So we assessed whether miR-34a and miR-140-5p contributes to the onset of cardiotoxicity induced by DOX. More specifically, miR-122 serves as a tumor suppressor by modulating multiple target genes.
This work is designed to highlight the role of miRNA as a novel biomarker for diagnosis and to evaluate whether miR-34a, miR-140-5p, miR-122 and their target genes were involved in mice suffering from Ehrlich Ascites carcinoma to investigate the anti-angiogenic efficacy of chitosan nanoparticles as carriers for doxorubicin to provide poly-loads safe anti-cancer drug.